Humira adalimumab: Additional Phase III data

Additional data from the double-blind, international Phase III ABILITY-1 trial in 179 patients with active non-radiographic axial spondyloarthritis showed that Humira significantly improved Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) scores at week 12 vs. placebo (reductions of 0.3 vs. 0.1

Read the full 409 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE